

Figure 1



Application No.: 10/822,943
Attorney Docket No.: 6659.200-US
Replacement Sheet

Figure 2



Application No.: 10/822,943
Attorney Docket No.: 6659.200-US
Replacement Sheet

Figure 3




Figure 4





a
*
TF activity (a.u./mg prot)
140
120
100
80
60
40
20
0
OA
RA
b
*
TFPI activity (a.u./mg prot)
8
6
4
2
0
OA
RA
c
TF Ag (ng/mg prot)
8
6
4
2
0
OA
RA
d
TF mRNA
(a.u. after GAPDH normalization)
100
80
60
40
20
0
OA
RA

Figure 5


a
TF activity (a.u./mg prot)
60
40
20
0
*
OA
RA
b
TFPI activity (a.u./mg prot)
4
3
2
1
0
*
OA
RA
c
TF Ag (ng/mg prot)
3
2
1
0
OA
RA
d
TF mRNA
(a.u. after GAPDH normalization)
70
60
50
40
30
20
10
0
OA
RA


Application No.: 10/822,943
Attorney Docket No.: 6659.200-US
Replacement Sheet

Figure 6




Application No.: 10/822,943
Attorney Docket No.: 6659.200-US
Replacement Sheet

Figure 7



Application No.: 10/822,943
Attorney Docket No.: 6659.200-US
Replacement Sheet
Figure 8






Figure 9

Marker	Cell type	Staining with Anti-TF antibody	Localization of double positive cells
CD3	T cell	-	None seen
CD31	Endothelium	-	None seen
	Subset of macrophages	± (few cells)	In the lining layer and sublining tissue
CD68	Macrophage	++	Abundant staining in the lining and sublining tissue
Vimentin	Fibroblast	++	Abundant staining in the lining and sublining tissue and perivascular areas